

Accepted Manuscript

Regulation of seizure-induced MeCP2 Ser421 phosphorylation in the developing brain

Evan C. Rosenberg, Jocelyn J. Lippman-Bell, Marcus Handy, Samantha S. Soldan, Sanjay Rakhade, Cristina Hilario-Gomez, Kaitlyn Folweiler, Leah Jacobs, Frances E. Jensen



PII: S0969-9961(18)30139-6
DOI: doi:[10.1016/j.nbd.2018.05.001](https://doi.org/10.1016/j.nbd.2018.05.001)
Reference: YNBDI 4163

To appear in: *Neurobiology of Disease*

Received date: 25 October 2017
Revised date: 23 March 2018
Accepted date: 3 May 2018

Please cite this article as: Evan C. Rosenberg, Jocelyn J. Lippman-Bell, Marcus Handy, Samantha S. Soldan, Sanjay Rakhade, Cristina Hilario-Gomez, Kaitlyn Folweiler, Leah Jacobs, Frances E. Jensen, Regulation of seizure-induced MeCP2 Ser421 phosphorylation in the developing brain. The address for the corresponding author was captured as affiliation for all authors. Please check if appropriate. Ynbdi(2017), doi:[10.1016/j.nbd.2018.05.001](https://doi.org/10.1016/j.nbd.2018.05.001)

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Regulation of seizure-induced MeCP2 Ser421 phosphorylation in the developing brain

Evan C. Rosenberg^{2,3*}, Jocelyn J. Lippman-Bell^{1,2,4*}, Marcus Handy¹, Samantha S. Soldan¹,
Sanjay Rakhade², Cristina Hilario-Gomez², Kaitlyn Folweiler¹, Leah Jacobs¹, Frances E.
Jensen^{1,2}

¹Perelman School of Medicine, University of Pennsylvania, Department of Neurology, Philadelphia, PA 19104 and ²Boston Children's Hospital, Department of Neurology, Boston, MA 02115, ³New York University Langone Medical Center, New York, NY 10016, ⁴Philadelphia College of Osteopathic Medicine, Department of Biomedical Sciences, Philadelphia, PA 19131. *ECR and JJJ contributed equally to this work. Current address for CHG is Istituto Italiano di Tecnologia, 16163 Genova, Italy.

Address correspondence to:

Frances E. Jensen, MD, FACP
Professor and Chair
Department of Neurology
Perelman School of Medicine, University of Pennsylvania
3400 Spruce Street
Philadelphia, PA 19104-4283
(215) 662-3360
frances.jensen@uphs.upenn.edu

Keywords:

MeCP2, Seizure, Rett Syndrome, autism spectrum disorder, AMPARs, LT-VGCCs

Abbreviations:

| | |
|----------|---|
| MeCP2 | – methyl CpG binding protein 2 |
| CP-AMPA | – calcium-permeable α -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors |
| NMDARs | – N-methyl-D-aspartate receptor |
| LT-VGCCs | – L-type voltage gated calcium channels |
| HS | – hypoxic seizures |
| ASD | – autism spectrum disorder |
| KCl | – potassium chloride |
| KA | – kainic acid |
| NBQX | – 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo[f]quinoxaline-2,3-dione |
| NASPM | – 1-Naphthyl acetyl spermine trihydrochloride |
| D-APV | – D-(-)-2-Amino-5-phosphonopentanoic acid |
| Nimo | – nimodipine |

Acknowledgements

We thank D. Talos for helpful comments on the manuscript and M. Greenberg for antibodies.

Funding Sources

This work was supported by NIH Grants NS 068161 (JJL), NS 031718 (FEJ), DP1 OD003347 (FEJ) (from the Office of the Director). The authors declare no conflict of interest.

Highlights

- Neonatal hypoxic seizures induce phosphorylation of MeCP2 S421, a key mediator of activity-dependent plasticity.
- Seizures also activate CaMKII T286, an upstream regulator of MeCP2 activity.
- Blockade of calcium-permeable AMPARs and I-type voltage gated calcium channels, both *in vitro* and *in vivo*, reverses early life seizure-induced MeCP2 phosphorylation.

Abstract:

Neonatal seizures disrupt normal synaptic maturation and often lead to later-life epilepsy and cognitive deficits. During early life, the brain exhibits heightened synaptic plasticity, in part due to a developmental overabundance of Cav1.2 L-type voltage gated calcium (Ca²⁺) channels (LT-VGCCs) and Ca²⁺-permeable AMPARs (CP-AMPA) lacking GluA2 subunits. We hypothesized that early-life seizures overactivate these channels, in turn dysregulating Ca²⁺-dependent signaling pathways including that of methyl-CPG-binding protein 2 (MeCP2), a transcription factor implicated in the autism spectrum disorder (ASD) Rett Syndrome. Here, we show that *in vivo* hypoxia-induced seizures (HS) in postnatal day (P)10 rats acutely induced phosphorylation of the neuronal-specific target of activity-dependent MeCP2 phosphorylation, S421, as well as its upstream activator CaMKII T286. We next identified mechanisms by which activity-dependent Ca²⁺ influx induced MeCP2 phosphorylation using *in vitro* cortical and hippocampal neuronal cultures at embryonic day (E)18+10 days *in vitro* (DIV). In contrast to the prevalent role of NMDARs in the adult brain, we found that both CP-AMPA and LT-VGCCs mediated MeCP2 S421 and CaMKII T286 phosphorylation induced by kainic acid (KA) or high

potassium chloride (KCl) stimulation. Furthermore, *in vivo* post-seizure treatment with the broad-spectrum AMPAR antagonist NBQX, the CP-AMPA blocker IEM-1460, or the LT-VGCC antagonist nimodipine blocked seizure-induced MeCP2 phosphorylation. Collectively, these results demonstrate that early-life seizures dysregulate critical activity-dependent developmental signaling pathways, in part via CP-AMPA and LT-VGCC activation, providing novel age-specific therapeutic targets for convergent pathways underlying epilepsy and ASDs.

Introduction

The neonatal brain exists in a heightened state of excitation, primed for activity-dependent synaptic plasticity, formation, and refinement (Rakhade and Jensen, 2009). This hyperexcitability, although ideal for learning and memory, renders the brain vulnerable to seizures (Ben Ari and Holmes, 2006; Jensen et al., 1992; Rakhade and Jensen, 2009; Wirrell et al., 2011). Early-life seizures can alter development and plasticity of neuronal circuitry (Hernan et al., 2013; Isaeva et al., 2013; Swann, 2004; Zhou et al., 2011), which may in turn lead to cognitive impairments and autistic-like behavior (Brooks-Kayal, 2010; Lippman-Bell et al., 2013; Lucas et al., 2011; Lugo et al., 2014). Notably, many genetic autism spectrum disorders (ASDs) exhibit early-onset seizures (Berg et al., 2011; Tuchman, 2013), indicating a convergence of cellular and molecular mechanisms in ASDs and seizures. Activity-dependent synaptogenesis and downstream signaling may be an important area for therapeutic target development in treating these disorders.

Hypoxic encephalopathy, the leading clinical cause of neonatal seizures (Glass and Ferriero, 2007; Minchom et al., 1987), can be refractory to conventional antiepileptic drugs and can result in later-life epilepsy and cognitive and behavioral deficits (Brooks-Kayal, 2011; Jensen, 2009; Rakhade and Jensen, 2009; Tekgul et al., 2006). Consistently, studies using our established model of hypoxic seizures (HS) have demonstrated that only 15-minute hypoxia during the early-life critical period can produce to profound, lasting deficits in naïve, wild type animals, including the development of later life autistic-like social behavioral deficits (Lippman-

Bell et al., 2013; Talos et al., 2012), subsequent spontaneous seizures (Rakhade et al., 2011), and increased susceptibility to later-life “second-hit” kainic acid-induced seizures (Koh et al., 2004). Similarly, prior studies using other models of early-life seizures demonstrated severe impairments in learning, cognition, and sociability in later-life (Castelhano et al., 2013; Chang et al., 2003; Dube et al., 2009; Holmes et al., 1998; Huang et al., 2002; Sayin et al., 2004); although notably, our paradigm of HS does not produce confounding effects of cell death seen in other models (Lippman-Bell et al., 2016; Rakhade et al., 2011; Sanchez et al., 2001). Interestingly, our findings have demonstrated that HS preserve the brain in an immature state, with strengthened excitatory synaptic strength (Rakhade et al., 2008), reduced silent synapses (Zhou et al., 2011), increased Ca^{2+} influx (Lippman-Bell et al., 2016), potentiated Ca^{2+} -dependent kinase signaling (Lippman-Bell et al., 2016; Rakhade et al., 2008; Sanchez et al., 2001; Talos et al., 2012) and glutamate receptor phosphorylation (Rakhade et al., 2008). Strikingly, each of these post-HS consequences are prevented by post-seizure blockade of the AMPA receptor (AMPA) subtype of excitatory glutamate receptors, but not NMDA receptor antagonists (Jensen et al., 1995; Jensen and Wang, 1996).

In contrast to the adult, in which NMDARs primarily mediate activity-dependent, synaptically-driven Ca^{2+} signaling (Zhou et al., 2006), the immature brain contains Ca^{2+} -permeable, GluA2-lacking AMPARs (Talos et al., 2006a; Talos et al., 2006b), which significantly contribute to developmentally relevant intracellular signaling (Cull-Candy et al., 2006; Henley and Wilkinson, 2016; Rakhade and Jensen, 2009). Furthermore, $\text{Ca}_v1.2$ LT-VGCC expression is also developmentally upregulated in this same period of the second postnatal week (Kramer et al., 2012; Morton et al., 2013; Schlick et al., 2010). Given the protective effects of AMPAR blockers in our early-life *in vivo* seizure model compared with other glutamate receptor antagonists (Jensen et al., 1995; Jensen and Wang, 1996), we asked whether over-activation of CP-AMPA and LT-VGCCs in early-life seizures might disrupt signaling pathways relevant to neurodevelopment.

Specifically, we examined whether AMPARs and LT-VGCCs regulate activity-dependent phosphorylation of the transcriptional regulator methyl CpG binding protein 2 (MeCP2) as one potential pathway linking early-life seizures to synaptic deficits. MeCP2 plays important roles in synaptic plasticity, dendritic development, and neuronal maturation during early postnatal life (Cohen et al., 2011; Feldman et al., 2016; Jiang et al., 2013; Kishi and Macklis, 2010; Luikenhuis et al., 2004; Mullaney et al., 2004; Shahbazian et al., 2002b; Zhou et al., 2006), and mutations in MeCP2 lead to the ASD Rett Syndrome (Amir et al., 1999). Furthermore, animal models of both neonatal hypoxic seizures (Lippman-Bell et al., 2013; Rakhade et al., 2011; Talos et al., 2012) and MeCP2 KO mice (Neul et al., 2010; Zhang et al., 2014) develop later-life ASD-like behavior, cognitive deficits, and increased seizure susceptibility, prompting the question of whether early-life seizures perturb MeCP2 function to initiate a process leading to synaptic and cognitive dysfunction.

Of the multiple phosphorylation sites that regulate MeCP2 function (Bellini et al., 2014), the neuronal-specific (Zhou et al., 2006) S421 site is highly regulated by activity, such as Schaffer collateral stimulation (Munoz et al., 2016), psychostimulant-induced plasticity (Deng et al., 2010; Deng et al., 2014), postsynaptic Ca^{2+} influx, and CaMKII T286 phosphorylation (Zhou et al., 2006). In older animals, NMDARs are the primary mediator of synaptically driven MeCP2 S421 phosphorylation (Zhou et al., 2006); however, we hypothesized that elevated expression of CP-AMPA and LT-VGCCs early in development may provide an additional route of Ca^{2+} entry into neurons (Morton et al., 2013; Rakhade and Jensen, 2009; Sanchez et al., 2001).

Here we present evidence that *in vivo* neonatal seizures and *in vitro* neuronal depolarization induce phosphorylation of MeCP2 and its upstream activator CaMKII. Further, we demonstrate that two developmentally-regulated targets, CP-AMPA and LT-VGCCs, mediate seizure-induced MeCP2 S421 phosphorylation. Our results highlight potential age-specific treatment options following early-life seizures, and provide evidence for at least one pathway of overlap between early-life seizures and ASDs.

Materials and Methods

Animals

All studies were performed on male Long–Evans rats (Charles River Laboratories, Wilmington, MA, 10 pups/litter). Animals were housed in a temperature-controlled animal care facility with a 12-hour light/dark cycle and monitored regularly. All procedures were approved by the Institutional Animal Care and Use Committees at Boston Children's Hospital and University of Pennsylvania, and in accordance with the NIH Guide for the Care and Use of Laboratory Animals. All efforts were made to minimize animal suffering and numbers.

Hypoxia-Induced Seizures

Hypoxic seizures (HS) were induced in postnatal day (P)10 pups as described (Sanchez et al., 2001). Pups were placed in an airtight chamber with a heating pad and exposed to graded 100% nitrogen infusion for 15 minutes, reducing O₂ concentrations to 7% O₂ for 8 minutes, 5% O₂ for 6 minutes, and 4% O₂ for 1 minute. Age- and weight-matched littermate control pups were removed from their dam and placed on a heating pad, but not exposed to hypoxia. Seizures were defined as automatisms followed by head and limb movements and myoclonic jerks. To reduce variability, only animals with >5 seizures were included in the study. Rats were sacrificed at 0.5, 1, 3, 6, and 24 hr following HS (along with normoxic littermate controls). For drug treatment studies, P10 rats were given an intraperitoneal injection of either 20mg/kg NBQX (Sigma, saline vehicle), 20mg/kg IEM-1460 (Tocris, saline vehicle), 5 or 10 mg/kg nimodipine (Sigma, 10% DMSO/50% polyethylene glycol/40% dH₂O vehicle), or corresponding vehicle, within 30 min post-HS.

Dissociated Cell Culture Preparation

Dissociated cortical and hippocampal neuronal cultures were prepared from Long-Evans rats at E17/18 as previously described (Xia et al., 1996). Dishes were coated with 50µg/ml Poly-

D-Lysine and 20 μ g/ml Laminin 24 hours before plating. Neurons were maintained in a Neurobasal solution (Gibco/Invitrogen), supplemented with B27 (Invitrogen), 100U/ml penicillin/streptomycin (Invitrogen), and 2mM L-glutamine (Sigma). Cells were plated at 1-1.5x10⁶ cells/well in 6 well plates for immunoblotting, and 1x10⁵ cells/well in 24 well plates for imaging.

Immunoblots

For *in vivo* studies, cortical tissue was dissected at designated time points following HS, combined from 3 rats per sample, rapidly frozen in ethanol, and stored at -80°C. Nuclear lysates were isolated as previously described (Wang et al., 2012) using 1 protease and phosphatase inhibitor cocktail tablet (Thermo) per 10 mL buffer.

For *in vitro* studies, cells were treated for 2hr with 1 μ M tetrodotoxin (TTX, Tocris), 100 μ M D-APV (Tocris), 50 μ M NBQX (Tocris), 150 μ M NASPM (Sigma), 5 μ M nimodipine (Tocris), 5 μ M KN-92 (Calbiochem), 5 μ M KN-93 (Calbiochem), and/or 1mM EGTA (Sigma). Neurons were then stimulated for 1hr with 100 μ M KA (Tocris) or 55 μ M KCl (Sigma). Following stimulation, cells were harvested in 1x Laemmli's Sample Buffer, prepared as whole-cell lysates, and run on gels as previously described (Talos et al., 2012).

For both *in vitro* and *in vivo* samples, total protein concentrations were measured using a Bradford protein assay (Bio-Rad). Samples were diluted for equal amounts of protein in each lane. Proteins were electrophoresed onto Bis-Tris gels, then transferred to polyvinylidene difluoride membranes (Bio-Rad). Immunoblots were incubated with primary antibodies at 4°C overnight (described below). After incubating with horseradish peroxidase-conjugated anti-rabbit IgG secondary antibodies (1:5000, Pierce), protein bands were visualized with enhanced chemiluminescence (Super-West Femto Maximum Sensitivity Substrate reagent, Thermo Fisher

Scientific) and measured with the Image Reader LAS-3000 system and Image Gauge v3.0 software (Fujifilm).

For analysis, we performed separate blots for phospho- and total MeCP2 proteins with identical samples, due to the low sensitivity of the antibody following multiple strippings. Blots were incubated with the following primary antibodies: phospho-MeCP2 (S421) (1:1000) and total-MeCP2 (1:1000, kind gifts from Dr. Michael Greenberg, Harvard Medical School), phospho-CaMKII (T286) (1:250, Cell Signaling), and pan-CaMKII (1:250, Cell Signaling). To control for loading, blots were stripped and imaged for β -actin (1:5000, Sigma) for *in vitro* whole cell and Lamin A/C (1:1000, Cell Signaling) or Sin3a (1:100, Millipore) for *in vivo* nuclear samples. Following loading control normalization, ratios of phospho-/total MeCP2 (or CaMKII) ratios were measured, and normalized to either vehicle treated condition (*in vitro*) or age-matched normoxic controls (*in vivo*). For total MeCP2 quantification, we considered both bands for analysis – the phosphorylated (upper) and dephosphorylated (lower) forms, as described (Zhou et al., 2006).

Calcium imaging analysis and controls

Ratiometric Ca^{2+} imaging was performed on cultures pretreated for 2hr with 1 μM tetrodotoxin (TTX, Tocris), loaded with 15-20 μM Fura-2 AM (Invitrogen) and 0.1% pluronic F-127 (Invitrogen) for 30 min, then washed for 30 min. (All solutions hereafter were made in warmed, oxygenated ACSF containing 1 μM TTX). After 10 min bath application of 100 μM D-APV (Tocris), cells were stimulated using fast (<2 min) treatment of 30 μM kainic acid (KA). After washout, cells were treated for 10 min with D-APV plus 50 μM NBQX (Tocris) or 150 μM 1-Naphthylacetyl Spermine (NASPM, Sigma), then stimulated with KA again. Images were captured every 5 seconds on a Nikon Eclipse TE-2000S inverted microscope PlanFluor 20X/0.50 objective ($\infty/0/17$, WD2.1). Changes in Ca^{2+} influx were assessed by change in

340/380nm excitation ratio from baseline in individual somas (using regions of interests) in NisElements software. In all cells with a greater than background response to KA, change in peak Ca^{2+} response to KA before and after NASPM or NBQX treatment was analyzed via by paired t-test. Intraccluster correlation was performed as described in detail previously (Aarts et al., 2014) to determine the effective n's. Two sets of control experiments were run alongside the primary experiments, in both cortical and hippocampal cultures: 1) Double stimulation with KA to ensure that the second stimulation does not degrade the calcium signal, and 2) Stimulation with KA with no prior antagonist treatment followed by APV application and an additional KA stimulation, to assess a baseline level for NMDAR presence in the cultures.

Immunocytochemistry

Surface receptor staining in live cultured neurons was performed as described (Hughes et al., 2010). Cells were incubated in culture media with an antibody directed against the extracellular domain of GluA2 (1:500, Millipore) for 1 hour at 37°C, then washed with conditioned media from adjacent wells and incubated with AlexaFluor 555 secondary antibody (Invitrogen) for 1 hour at 37°C. Cells were then washed and fixed in 4% paraformaldehyde, 4% sucrose in PBS for 10 min, washed, permeabilized with cold 0.2% Triton X-100 for 5 min, and blocked in 10% normal goat serum/0.1% Triton X for 1 hour at room temperature. Cells were then labeled with antibodies against GluA1 (1:500, Abcam) and MAP2 (1:500, Millipore) to label dendrites. Antibodies were visualized with the appropriate AlexaFluor secondaries. Cells were imaged using a Zeiss LSM710 confocal microscope with an oil-immersion 63x 1.7 NA objective. Colocalization analyses were performed via Image J and Icy (<http://icy.bioimageanalysis.org>) software. Regions of interest were traced around apical dendrites within the MAP2 channel, and % puncta colocalization between GluA1 and GluA2 puncta within a 0.5µm radius was determined via the Icy Spot Detector Plugin. All analyses were performed blinded to developmental age.

Statistical Analysis

Group data were expressed as mean \pm SEM, with n representing the number of cortical samples (*in vivo*) or coverslips (*in vitro*), unless stated otherwise. Ca²⁺ imaging experiments were analyzed via paired 2-way student's t-test or 1-way ANOVA. For multiple comparisons across >2 conditions, one-way ANOVA followed by post hoc Tukey's or Bonferroni multiple comparison tests were used. For the *in vivo* post-seizure time-course experiments, two tailed t-tests corrected for multiple comparisons with the Holm-Sidak method were used. Statistical significance was defined as $p < 0.05$.

Results

***In vivo* hypoxic seizures (HS) in P10 rats induce phosphorylation of MeCP2 S421 and CaMKII T286**

Hypoxic seizures (HS) in neonatal rats (P10) induce rapid post-translational modifications and synaptic accumulation of AMPARs (Rakhade et al., 2012; Rakhade et al., 2008) and dysregulate several intracellular signaling cascades (Tallos et al., 2012). We hypothesized that HS at P10, an age with high levels of CP-AMPA receptors and Ca_v1.2 channels (Morton et al., 2013; Tallos et al., 2006a), would increase phosphorylation of MeCP2 and its upstream activator CaMKII. Indeed, cortical tissue removed post-HS showed a significant increase in MeCP2 S421 phosphorylation at 3 hrs post-HS (Suppl. Fig. 1, Fig. 1A: 148 \pm 11% vs. normoxic controls, $p=0.003$), and elevated CaMKII T286 phosphorylation at 1 hr post-HS (Fig. 1B: 184 \pm 20% $p=0.009$). These findings indicate that *in vivo* early-life seizures induce transient activity-dependent regulation of CaMKII and MeCP2.

Identification of functional CP-AMPA receptors at E18+10DIV

To determine whether CP-AMPA receptors facilitate HS-mediated MeCP2 and CaMKII phosphorylation in early life, we next examined their role in activity-dependent signaling in

developing cortical and hippocampal primary neurons *in vitro*. We hypothesized that GluA2-lacking CP-AMPA receptors in young (E18+10DIV) neuronal cultures (Yin et al., 1999) and early postnatal rodent and human brains *in vivo* (Tallos et al., 2006a; Tallos et al., 2006b) would provide an added source of synaptically driven Ca^{2+} to supplement signaling through NMDARs reported previously in more mature neurons (Zhou et al., 2006). To confirm the presence of CP-AMPA receptors, we measured neuronal Ca^{2+} influx via Fura-2 Ca^{2+} imaging in E18+10DIV cultured cortical and hippocampal neurons stimulated by kainic acid (KA, 30 μM). KA-induced Ca^{2+} influx was reduced by the NMDAR antagonist D-APV (100 μM), suggesting that NMDA receptors contribute to about 25% of Ca^{2+} influx (Fig. 2A-B, normalized mean peak ratio in cortex (C): 100 \pm 2% KA only vs. 74 \pm 3% KA+APV, $p < 0.0001$; and hippocampus (H): 100 \pm 3% KA only vs. 73 \pm 3% KA+APV, $p < 0.0001$). The remaining NMDAR-insensitive Ca^{2+} influx (Fig. 2A,B, KA+APV C: 100 \pm 3%, H: 100 \pm 3%) was further decreased by both the AMPAR antagonist NBQX (50 μM) (C: 3 \pm 2%, H: 31 \pm 2%, vs. KA+APV condition, $p < 0.0001$) and 150 μM NASPM, a specific blocker of Ca^{2+} permeable, GluA2-deficient AMPARs (C: 79 \pm 3%, H: 84 \pm 3%, $p < 0.0001$). Control neurons responded equally to dual KA stimulation (Suppl. Fig. 2A), excluding the possibility that reduced Ca^{2+} influx was due to repeated KA stimulation. Together, these findings confirm that CP-AMPA receptors facilitate part of the non-NMDAR-mediated Ca^{2+} influx at E18+10DIV.

Given the critical role of the GluA2 subunit in regulating Ca^{2+} permeability, we next used immunocytochemistry to measure the percentage of GluA1 subunits colocalized with GluA2. Consistent with prior reports (Kumar et al., 2002; Pickard et al., 2000; Yin et al., 1999), only about 31 \pm 4% of GluA1-containing AMPARs were colocalized with GluA2 at the earlier E17/18+10DIV time point vs. 61 \pm 2% by 13DIV (Suppl. Fig. 3, $p < 0.0006$), suggesting a predominance of GluA2-lacking AMPARs at this developmental stage, supported by *in vivo* observations in intact developing brain (Henley and Wilkinson, 2016). Combined with Ca^{2+} imaging, this suggests that GluA2-lacking CP-AMPA receptors in early life are poised to mediate activity-dependent Ca^{2+} signaling.

CP-AMPA and LT-VGCCs mediate MeCP2 phosphorylation in E18+10DIV cell cultures

We next investigated the role of CP-AMPA in activity-dependent MeCP2 phosphorylation *in vitro*. We predicted that elevated AMPAR-mediated Ca^{2+} influx at E18+10DIV, an age analogous to P10 in rodents or term to infancy in humans (Rakhade and Jensen, 2009), may provide age-specific seizure-induced hyperphosphorylation of MeCP2. We first used kainic acid (KA, 100 μM) stimulation to target ionotropic glutamate receptors and isolate the effects of upstream mediators on MeCP2 phosphorylation in E18+10DIV cultures (Suppl Fig. 4). As in older (12DIV) cultures (Zhou et al., 2006), synaptic stimulation induced MeCP2 S421 phosphorylation in both cortical (Fig. 3A) and hippocampal neurons (Fig. 3B). However, unlike prior studies, 100 μM D-APV was not sufficient to prevent MeCP2 phosphorylation in DIV10 cortical neurons (Ctx: Fig. 3A: $76 \pm 13\%$ vs. KA, NaOH+DMSO treated controls, $p=0.072$) or hippocampal neurons (H: Fig. 3B: $89 \pm 13\%$, $p=0.888$), suggesting that MeCP2 phosphorylation requires additional Ca^{2+} influx from alternate, non-NMDAR sources. In the presence of APV, MeCP2 phosphorylation was reduced by administration of either 50 μM NBQX (Ctx: Fig. 3A: $0 \pm 0.3\%$, $p<0.0001$; H: Fig. 3B: $3 \pm 5\%$, $p<0.0001$), or the CP-AMPA antagonist NASPM (150 μM) (Ctx: $12 \pm 2\%$, $p<0.0001$; H: $30 \pm 9\%$, $p<0.0001$).

With respect to the relative efficacy of LT-VGCCs in MeCP S421 phosphorylation, we found that nimodipine (5 μM , with D-APV) also significantly decreased MeCP2 phosphorylation following KA-induced depolarization (Ctx: Fig. 3A: $4 \pm 1\%$, $p<0.0001$; H: Fig. 3B: $21 \pm 6\%$, $p<0.0001$). However, addition of nimodipine to D-APV and NASPM did not add any additional reduction of MeCP2 S421 phosphorylation to D-APV and NASPM alone in cortex ($p=0.973$) and hippocampus ($p=0.790$). Together, these findings suggest that both CP-AMPA and LT-VGCCs each mediate essential Ca^{2+} influx to induce MeCP2 S421 phosphorylation in early life.

To examine the upstream mediators of Ca^{2+} influx in generalized neuronal depolarization, we stimulated neurons using high [KCl] and performed similar pharmacologic

blockades as above. D-APV alone did not reverse KCl-mediated MeCP2 phosphorylation in cortical (Fig. 3C: $87 \pm 21\%$, $p=0.9637$) or hippocampal neurons (Fig. 3D: $73 \pm 21\%$, $p=0.373$). In contrast, phosphorylation was reduced (in the presence of D-APV) by NBQX (Ctx: Fig. 3C: $35 \pm 5\%$, $p=0.0215$; H: Fig. 3D: $21 \pm 6\%$, $p=0.0082$), NASPM (Ctx: Fig. 3C: $32 \pm 13\%$, $p=0.0241$; H: Fig. 3D: $11 \pm 6\%$, $p=0.0015$), and nimodipine (Ctx: Fig. 3C: $10 \pm 6\%$, $p=0.0005$; H: Fig. 3D: $0 \pm 1\%$, $p=0.0002$). Nimodipine in the presence of NASPM and D-APV did not further reduce MeCP2 phosphorylation over CP-AMPA + NMDARs alone (Ctx: $p=0.4352$; H: $p=0.8012$). Overall, these results indicate that both CP-AMPA and LT-VGCCs collectively contribute to MeCP2 S421 phosphorylation via two parallel pathways leading to depolarization-induced Ca^{2+} influx.

CaMKII T286 phosphorylation is upstream of MeCP2 phosphorylation and mediated by CP-AMPA and LT-VGCCs in E18+10DIV cultures

Prior studies indicate that phosphorylation of MeCP2 S421 requires both CaMKII T286 phosphorylation and intracellular Ca^{2+} influx (Zhou et al., 2006), supported by our *in vivo* findings of sequential, seizure-induced activation of CaMKII and MeCP2 (Fig. 1). Consistent with these results, in both cortical (Fig. 4A) and hippocampal E18+10DIV cultures (Fig. 4B), phosphorylation of MeCP2 S421 was blocked by $5 \mu\text{M}$ KN93, a potent inhibitor of CaMKII (Ctx: $10 \pm 3\%$, $p<0.0001$; H: $3 \pm 1\%$, $p<0.0001$), but not its inactive form, KN92 ($5 \mu\text{M}$) (Ctx: $99 \pm 3\%$, $p>0.9999$; H: $97 \pm 3\%$, $p>0.9999$). Additionally, the Ca^{2+} chelator EGTA (1mM) reduced phosphorylation of MeCP2 S421 (Ctx: $72 \pm 7\%$, $p=0.0005$; H: $66 \pm 7\%$, $p<0.0001$), as did the membrane-permeable form, $100 \mu\text{M}$ EGTA-AM in cortical (Fig. 4C: $64 \pm 6\%$, $p=0.0001$) and hippocampal (Fig. 4D: $53 \pm 13\%$, $p=0.0057$) neuronal cultures. Thus, CaMKII and intracellular Ca^{2+} regulate MeCP2 S421 phosphorylation at E18+10DIV.

As CaMKII is upstream of MeCP2 phosphorylation, we hypothesized that CaMKII pT286 required Ca^{2+} influx through the same channels as MeCP2 S421 phosphorylation. As with

MeCP2, pre-treatment with D-APV did not fully reverse KA-induced CaMKII phosphorylation (Ctx: Fig. 5A: $81 \pm 11\%$, $p=0.2921$; H: Fig. 5B: $86 \pm 9\%$, $p=0.5213$). However, CaMKII phosphorylation was significantly reduced (in the presence of D-APV) with the addition of NBQX (Ctx: Fig. 5A: $18 \pm 4\%$, $p<0.0001$; H: Fig. 5B: $21 \pm 3\%$, $p<0.0001$), NASPM, (Ctx: Fig. 5A: $25 \pm 5\%$, $p=0.0001$; H: Fig. 5B: $28 \pm 7\%$, $p<0.0001$), and nimodipine (Ctx: Fig. 5A: $23 \pm 9\%$, $p=0.0002$; H: Fig. 5B: $33 \pm 6\%$, $p<0.0001$). However, LT-VGCC blockade did not reduce CaMKII T286 phosphorylation more than NASPM + D-APV alone (Ctx: $p=0.7365$; H: $p=0.929$). These results demonstrate that Ca^{2+} entry through both CP-AMPA and LT-VGCCs contribute to activity-dependent CaMKII T286 phosphorylation in immature cortical and hippocampal neurons, consistent with the effects on MeCP2 S421 phosphorylation.

***In vivo* HS-induced phosphorylation of MeCP2 S421 is prevented by AMPAR and LT-VGCC blockade**

We previously showed that post-seizure *in vivo* treatment with NBQX prevents later-life seizures, altered synaptic plasticity, and autistic-like social deficits (Lippman-Bell et al., 2013; Zhou et al., 2011), whereas NMDAR antagonists do not prevent consequences of HS at this developmental time point (Jensen et al., 1995; Jensen and Wang, 1996). Given the *in vitro* evidence for CP-AMPA in dysregulating MeCP2, we examined the effects of NBQX and the systemically administrable CP-AMPA-specific inhibitor IEM-1460 (Szczurowska and Mares, 2015) on MeCP2 S421 phosphorylation *in vivo*, immediately after HS. Consistent with our prior *in vivo* post-HS outcomes (Lippman-Bell et al., 2013; Lippman-Bell et al., 2016; Rakhade et al., 2008), administration of either 20 mg/kg NBQX or 20 mg/kg IEM-1460 (i.p.) (Magazanik et al., 1997; Szczurowska and Mares, 2015) significantly attenuated the increased MeCP2 S421 phosphorylation 3 hrs post-HS (Fig. 6: Control(C)+Vehicle(V) $100 \pm 8\%$, HS+V $157 \pm 11\%$ normalized to mean C+V control, HS+NBQX $81 \pm 8\%$, HS+IEM-1460 $106 \pm 11\%$; ANOVA

$p=0.002$, with post-hoc Tukey's comparisons: C+V vs. HS+V $p=0.0003$, HS+V vs. HS+NBQX $p<0.0001$, HS+V vs. HS+IEM-1460 $p=0.0099$). We additionally confirmed that IEM-1460 reduced activity-dependent MeCP2 phosphorylation in cultured neurons *in vitro* cortical (Fig. 4C: $76\pm5\%$, $p=0.0039$) and hippocampal (Fig. 4D: $70\pm8\%$, $p=0.0361$) cell cultures. Paralleling our *in vitro* results, *in vivo* treatment with nimodipine reduced post-HS MeCP2 phosphorylation at 10 mg/kg, i.p. (Fig. 6: HS+NIMO $103\pm9\%$, HS+V vs. HS+NIMO $p=0.0051$), but not at a previously reported anti-convulsive dose of 5 mg/kg i.p. (Suppl. Fig. 5B) (Radzicki et al., 2013; Shitak et al., 2006; Shitak et al., 2007). *In vivo* NBQX, IEM-1460, and nimodipine administration did not affect baseline MeCP2 phosphorylation in control rats (Suppl. Fig. 5A,B). Collectively, our *in vivo* findings support a critical role for CP-AMPA and LT-VGCCs in mediating seizure-induced MeCP2 phosphorylation during early development.

Discussion

In early life, both seizures and autism share a developmental dysregulation of synaptogenesis and destabilized synaptic function, representing a potential overlap of underlying cellular mechanisms (Eichler and Meier, 2008). Early-life seizures contribute to later-life epilepsy and associated autistic-like behavioral deficits (Lippman-Bell et al., 2013; Talos et al., 2012), and epilepsy and autism often co-occur in neurodevelopmental disorders such as Rett Syndrome (Moretti et al., 2005; Neul et al., 2010; Pobbe et al., 2012; Tuchman, 2013). These findings suggest that seizures may dysregulate development in part through key activity-dependent neurodevelopmental signaling molecules implicated in ASDs, such as MeCP2. As neuronal activity modulates MeCP2 S421 function (Zhou et al., 2006), and neonatal seizures disrupt CP-AMPA signaling (Rakhade et al., 2008; Sanchez et al., 2001; Zhou et al., 2011), the primary aim of this study was to determine if early-life seizures perturb MeCP2 through activation of Ca^{2+} via CP-AMPA. We discovered that neonatal seizures elevate MeCP2 S421 phosphorylation *in vivo* 3 hours post-seizure, and increase CaMKII T286 phosphorylation 1 hr

post-seizure. Furthermore, both Ca^{2+} -permeable AMPARs and LT-VGCCs mediated a NMDAR-insensitive component of activity-dependent MeCP2 phosphorylation (Zhou et al., 2006).

Our findings that HS induce MeCP2 S421 phosphorylation align with prior reports of elevated MeCP2 S421 phosphorylation following kainic acid (KA)-induced seizure (Tao et al., 2009), pentylenetetrazole (PTZ)-induced seizure (Zhou et al., 2006), LTP-like high frequency stimulation (2x 100Hz, 20s interval) (Li et al., 2011), and bicuculline stimulation (Buchthal et al., 2012), as well as psychostimulant-induced plasticity (Deng et al., 2010; Deng et al., 2014). Furthermore, out of four identified activity-dependent sites of MeCP2 phosphorylation, only S421 was elevated in the slowly migrating western blot band following kainic acid-induced seizures in rats (Tao et al., 2009), suggesting that S421 phosphorylation may represent a unique mediator of seizure-induced plasticity in rats. While some studies noted seizure-induced MeCP2 S421 phosphorylation as early as 30 minutes to one hour post seizure (Buchthal et al., 2012; Zhou et al., 2006), we note peak changes at the 3 hour time point, which may reflect experimental differences using our somewhat milder, yet physiologically relevant induction protocol (15 min. hypoxia vs. chemoconvulsants). To our knowledge, our study is the first to examine a prolonged time course of early life seizure-induced MeCP2 phosphorylation up to 24 hours, therefore we do not know in prior studies whether or when the phosphorylation returned to baseline.

Similar to the current study, we also previously observed sequential changes in other activity-dependent kinases after HS, with elevated CaMKII, PKA, and PKC activity at 1 hr post-HS (Rakhade et al., 2008), and successive activation of members of the mTOR pathway (e.g. pERK/pAKT at 3 hours, p-p70S6 kinase at 12 hours, pS6 kinase at 24 hours) (Tallos et al., 2012). Thus, HS likely produce multifocal, transient effects on many signaling pathways, with MeCP2 as one potential (but not exclusive) target for blockade. As many of these canonical signaling pathways are essential for proper synapse development and plasticity, we propose that even transient HS during the critical period may dysregulate these conduits (e.g. CaMKII, mTOR, MeCP2), which may in turn disrupt later-life cognition. Consistent with this idea, early-

life impairments in MeCP2 function can disrupt visual critical period plasticity, leading to chronic deficits (He et al., 2014; Krishnan et al., 2015). In future studies, it would be valuable to know if acute or chronic blockade of MeCP2 S421 phosphorylation (e.g. phosphomutant MeCP2^{S421A} mice (Cohen et al., 2011)) prevent later-life cognitive deficits or spontaneous seizure development following early-life HS (Koh et al., 2004; Lippman-Bell et al., 2013; Rakhade et al., 2011; Talos et al., 2012). We would predict that decreasing the level of S421 phosphorylation would rescue seizure-induced behavioral deficits, however it is a delicate balance; rendering S421 completely nonfunctional impairs social preference for novelty in a similar fashion to what we have seen following early-life HS (Cohen et al., 2011).

Neurons with elevated MeCP2 S421 phosphorylation share some phenotypic overlap with the MeCP2 KO *hypomorph* condition, as both demonstrate elevated expression of downstream transcriptional targets such as *BDNF* *in vitro* (Chen et al., 2003; Martinowich et al., 2003; Zhou et al., 2006). However, other studies *in vivo* demonstrate reduced *BDNF* expression in MeCP2 KO mice vs. WT (Chang et al., 2006), perhaps attributable to reduced network activity in MeCP2 KO mice (Dani et al., 2005). Further, newer reports suggest that MeCP2 can serve as a transcriptional activator (Chahrour et al., 2008; Chang et al., 2006) and global chromatin regulator (Cohen et al., 2011) in addition to a repressor (Chen et al., 2003; Zhou et al., 2006), indicating that MeCP2 phosphorylation changes acquired as a result of seizures may have far reaching, unpredictable effects on downstream immediate early gene and neurotrophin expression. Future studies are warranted to examine how seizure-induced elevated MeCP2 S421 phosphorylation regulate target genes and signaling pathways *in vivo*.

We identified two novel, age-specific targets of seizure-induced MeCP2 S421 phosphorylation *in vitro* and *in vivo*: CP-AMPA receptors and LT-VGCCs. Elevated CP-AMPA receptor expression during early life (Rakhade and Jensen, 2009) not only contributes to the synaptic plasticity needed for synaptic refinement, but also likely provokes the progression of epileptogenesis (Rakhade and Jensen, 2009; Talos et al., 2006b), as NBQX, but not NMDAR

antagonists, prevents increased seizure susceptibility following HS at P10 (Jensen et al., 1995; Jensen and Wang, 1996). To examine the mechanisms underlying activity-dependent activation of CP-AMPA receptors in early life, we used E18+10DIV cultured neurons, which express a high level of CP-AMPA receptors and MeCP2 (Yin et al., 1999). Unlike previous studies suggesting a dominance of NMDAR-mediated MeCP2 phosphorylation in older (E18+12DIV) neuronal cultures (Zhou et al., 2006), we found that two days earlier, at E18+10DIV, CP-AMPA receptors contribute to synaptically driven Ca^{2+} influx for activity-dependent MeCP2 phosphorylation, as evidenced by NASPM and NBQX significantly blocking KA-induced Ca^{2+} influx above that of APV alone.

Our *in vitro* model provides two unique paradigms to study MeCP2 phosphorylation: kainic acid (KA)-induced stimulation of ionotropic glutamate receptors and high [KCl]-induced neuronal depolarization, to account for additional non-synaptic effects. This model attempts to recreate elevated excitability hours post hypoxic-seizures *in vivo* (Lippman-Bell et al., 2016; Rakhade et al., 2008), while avoiding acute effects due to hypoxia itself, such as primary changes in levels of ATP, adenosine, pH, and neurotransmitter release that precede later hyperexcitability (Di Filippo et al., 2008; Mukandala et al., 2016). The *in vitro* studies provide an assay to systematically and pharmacologically target the receptors and channels that mediate MeCP2 phosphorylation, however bath application of KA or KCl may not produce the same activation and time course as synaptically released glutamate *in vivo*. Therefore, we also demonstrate that both the AMPAR antagonist NBQX and the novel CP-AMPA blocker IEM-1460 prevented seizure-induced MeCP2 phosphorylation *in vivo*, further underscoring the relevance of our *in vitro* model.

Additionally, *in vivo* blockade of LT-VGCCs via nimodipine at higher (10 mg/kg), but not lower (5 mg/kg) doses, reduced HS-induced MeCP2 phosphorylation. Our *in vitro* findings suggest that Ca^{2+} influx from LT-VGCCs and CP-AMPA receptors both individually contribute to MeCP2 phosphorylation, and both pathways likely converge on a common endpoint. Notably, LT-VGCCs are developmentally upregulated during early postnatal development (Kramer et al.,

2012; Morton et al., 2013; Schlick et al., 2010), and have been implicated in promoting both epileptogenesis (Beck et al., 1998; Siwek et al., 2012; Speckmann et al., 1993; Stiglbauer et al., 2017) and ASD-like behavior (Jinnah et al., 1999); Ca^{2+} influx–promoting mutations in LT-VGCCs cause Timothy Syndrome, a rare genetic form of ASD (Bader et al., 2011; Barrett and Tsien, 2008; Splawski et al., 2004).

Thus, both LT-VGCCs and CP-AMPA receptors appear to have a developmentally regulated, privileged role for MeCP2 S421 phosphorylation, even during a period when NMDARs contain an elevated NR2B:NR2A subunit ratio with transiently enhanced Ca^{2+} permeability, albeit with slower kinetics (Monyer et al., 1994; Yashiro and Philpot, 2008). In comparing the role of AMPARs and LT-VGCCs to seizure-induced MeCP2 phosphorylation, we recently found that NASPM, but not nimodipine or D-APV, limit elevated Ca^{2+} influx in acute hippocampal slices from rats post-HS at P10 (Lippman-Bell et al., 2016). Further studies may be required to fully understand the interactions between AMPARs and LT-VGCCs on MeCP2 S421 phosphorylation in the *in vivo* preparation.

MeCP2 likely plays a pivotal role in regulating activity-dependent gene transcription important for neural function, maturation of spine density, neuronal connectivity, dendritic arborization, behavior (Cohen et al., 2011; Jiang et al., 2013; Kishi and Macklis, 2010; Luikenhuis et al., 2004; Mullaney et al., 2004; Shahbazian et al., 2002b; Zhou et al., 2006), and multiple forms of synaptic plasticity, including synaptic scaling (Blackman et al., 2012; Qiu et al., 2012; Zhong et al., 2012) and Hebbian plasticity (Li et al., 2011; Moretti et al., 2006; Munoz et al., 2016; Weng et al., 2011). Mouse models of Rett Syndrome with decreased or blocked expression of MeCP2 show impaired LTP in area CA1 of the hippocampus (Asaka et al., 2006; Weng et al., 2011), changes in glutamate receptor expression including decreased NR2A (Asaka et al., 2006), behavioral deficits (Neul et al., 2010), and increased spontaneous seizure susceptibility (D'Cruz et al., 2010; Shahbazian et al., 2002a; Zhang et al., 2014). All of these changes also occur in an acquired manner in the HS neonatal seizure model (Bo et al., 2004;

Lippman-Bell et al., 2013; Zhou et al., 2011), which we now show alters MeCP2 S421 phosphorylation. The phenotypic and molecular overlap between HS and MeCP2 KO mice raises the important possibility that seizures themselves impair synaptic function and may lead to later life cognitive and behavioral deficits in part by dysregulating physiologic MeCP2 function in the immature brain.

Our study provides key evidence for AMPARs as an *upstream* mediator of MeCP2 phosphorylation, complementing prior findings of AMPARs as a key downstream component of MeCP2-mediated signaling. Indeed, GluA1 and GluA2 subunit trafficking is impaired both in LTP in MeCP2 KO mice (Li et al., 2016), and homeostatic synaptic scaling with MeCP2 knockdown (Blackman et al., 2012; Qiu et al., 2012). Taken together, these data suggest that AMPARs (along with LT-VGCCs) play a crucial role in a NMDAR-insensitive component of seizure-induced MeCP2-regulated signaling, which could in turn trigger later-life cognitive deficits or spontaneous seizures. Consistent with this hypothesis, IEM-1460 reduced hyperexcitability following both PTZ (Szczurowska and Mares, 2015) and pilocarpine-induced seizures (Malkin et al., 2016), and nimodipine prevented later-life impairments in spatial memory following PTZ kindling (Wang et al., 2008) as well as behavioral deficits after focal ischemic-reperfusion excitotoxicity (Babu and Ramanathan, 2011). Combined with prior knowledge that both CP-AMPARs (Fortin et al., 2010; Park et al., 2016) and LT-VGCCs (Da Silva et al., 2013; Grover and Teyler, 1990) play a key role in some forms of synaptic plasticity, we predict that both of these targets will play an essential role in HS-induced cognitive deficits later in life, prompting further study.

HS-induced signaling through AMPARs and LT-VGCCs may also mediate changes in other proteins implicated in Rett Syndrome, such as CDKL5 (Tao et al., 2004; Weaving et al., 2004), which is known to be highly regulated by activity (Rusconi et al., 2011; Zhou et al., 2006). CDKL5 directly binds and phosphorylates MeCP2 *in vitro* and *in vivo* (Mari et al., 2005) and regulates dendritic morphology and synapse development (Chen et al., 2010; Mari et al., 2005;

Zhou et al., 2006; Zhu et al., 2013), suggesting that they may share common signaling pathways. Future studies should address whether seizure-induced CaMKII-MeCP2 activation cooperates spatially and temporally with CDKL5-MeCP2 phosphorylation, and if these interactions are implicated in Rett Syndrome pathophysiology.

Collectively, we propose that the AMPAR-MeCP2 pathway, along with that of the LT-VGCCs, may provide a therapeutically targetable mechanism for post-HS long-term behavioral changes, presenting an exciting area of further research relating to the interaction between epilepsy and autism in early postnatal brain development.

Conclusions

In this study, we provide novel evidence that seizures in the wild-type early-life brain dysregulate MeCP2, a critical mediator of synaptic development that has been implicated in the ASD Rett Syndrome. Further, we demonstrate that systemically blocking Ca^{2+} -permeable AMPARs (CP-AMPA) and LT-VGCCs, two targets overexpressed in the immature brain, reverses seizure-induced MeCP2 phosphorylation. Furthering our understanding of these age-specific molecular pathways will lead to improved treatments for both epilepsy and ASDs, and better elucidate the interaction between these disorders.

References

- Aarts, E., et al., 2014. A solution to dependency: using multilevel analysis to accommodate nested data. *Nat Neurosci.* 17, 491-6.
- Amir, R. E., et al., 1999. Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. *Nat Genet.* 23, 185-8.
- Asaka, Y., et al., 2006. Hippocampal synaptic plasticity is impaired in the Mecp2-null mouse model of Rett syndrome. *Neurobiol.Dis.* 21, 217-227.
- Babu, C. S., Ramanathan, M., 2011. Post-ischemic administration of nimodipine following focal cerebral ischemic-reperfusion injury in rats alleviated excitotoxicity, neurobehavioural alterations and partially the bioenergetics. *Int J Dev Neurosci.* 29, 93-105.
- Bader, P. L., et al., 2011. Mouse model of Timothy syndrome recapitulates triad of autistic traits. *Proc Natl Acad Sci U S A.* 108, 15432-7.
- Barrett, C. F., Tsien, R. W., 2008. The Timothy syndrome mutation differentially affects voltage- and calcium-dependent inactivation of CaV1.2 L-type calcium channels. *Proc Natl Acad Sci U S A.* 105, 2157-62.
- Beck, H., et al., 1998. Voltage-dependent Ca²⁺ currents in epilepsy. *Epilepsy Res.* 32, 321-32.
- Bellini, E., et al., 2014. MeCP2 post-translational modifications: a mechanism to control its involvement in synaptic plasticity and homeostasis? *Front Cell Neurosci.* 8, 236.
- Ben Ari, Y., Holmes, G. L., 2006. Effects of seizures on developmental processes in the immature brain. *Lancet Neurol.* 5, 1055-1063.
- Berg, A. T., et al., 2011. Risk and correlates of autism spectrum disorder in children with epilepsy: a community-based study. *J Child Neurol.* 26, 540-7.
- Blackman, M. P., et al., 2012. A critical and cell-autonomous role for MeCP2 in synaptic scaling up. *J Neurosci.* 32, 13529-36.
- Bo, T., et al., 2004. Long-term effects of seizures in neonatal rats on spatial learning ability and N-methyl-D-aspartate receptor expression in the brain. *Brain Res Dev Brain Res.* 152, 137-42.
- Brooks-Kayal, A., 2010. Epilepsy and autism spectrum disorders: are there common developmental mechanisms? *Brain Dev.* 32, 731-8.
- Brooks-Kayal, A., 2011. Molecular mechanisms of cognitive and behavioral comorbidities of epilepsy in children. *Epilepsia.* 52, 13-20.
- Buchthal, B., et al., 2012. Nuclear calcium signaling controls methyl-CpG-binding protein 2 (MeCP2) phosphorylation on serine 421 following synaptic activity. *J Biol Chem.* 287, 30967-74.
- Castelhano, A. S., et al., 2013. Altered anxiety-related and abnormal social behaviors in rats exposed to early life seizures. *Front Behav Neurosci.* 7, 36.
- Chahrour, M., et al., 2008. MeCP2, a key contributor to neurological disease, activates and represses transcription. *Science.* 320, 1224-9.
- Chang, Q., et al., 2006. The disease progression of Mecp2 mutant mice is affected by the level of BDNF expression. *Neuron.* 49, 341-8.
- Chang, Y. C., et al., 2003. Febrile seizures impair memory and cAMP response-element binding protein activation. *Ann.Neurol.* 54, 706-718.
- Chen, Q., et al., 2010. CDKL5, a protein associated with rett syndrome, regulates neuronal morphogenesis via Rac1 signaling. *J Neurosci.* 30, 12777-86.
- Chen, W. G., et al., 2003. Derepression of BDNF transcription involves calcium-dependent phosphorylation of MeCP2. *Science.* 302, 885-889.
- Cohen, S., et al., 2011. Genome-wide activity-dependent MeCP2 phosphorylation regulates nervous system development and function. *Neuron.* 72, 72-85.
- Cull-Candy, S., et al., 2006. Regulation of Ca²⁺-permeable AMPA receptors: synaptic plasticity and beyond. *Curr Opin Neurobiol.* 16, 288-97.
- D'Cruz, J. A., et al., 2010. Alterations of cortical and hippocampal EEG activity in MeCP2-deficient mice. *Neurobiol Dis.* 38, 8-16.
- Da Silva, W. C., et al., 2013. Memory reconsolidation and its maintenance depend on L-voltage-dependent calcium channels and CaMKII functions regulating protein turnover in the hippocampus. *Proc Natl Acad Sci U S A.* 110, 6566-70.

- Dani, V. S., et al., 2005. Reduced cortical activity due to a shift in the balance between excitation and inhibition in a mouse model of Rett syndrome. *Proc Natl Acad Sci U S A.* 102, 12560-5.
- Deng, J. V., et al., 2010. MeCP2 in the nucleus accumbens contributes to neural and behavioral responses to psychostimulants. *Nat Neurosci.* 13, 1128-36.
- Deng, J. V., et al., 2014. MeCP2 phosphorylation limits psychostimulant-induced behavioral and neuronal plasticity. *J Neurosci.* 34, 4519-27.
- Di Filippo, M., et al., 2008. Plasticity and repair in the post-ischemic brain. *Neuropharmacology.* 55, 353-62.
- Dube, C. M., et al., 2009. Cognitive dysfunction after experimental febrile seizures. *Exp Neurol.* 215, 167-77.
- Eichler, S. A., Meier, J. C., 2008. E-I balance and human diseases - from molecules to networking. *Front Mol Neurosci.* 1, 2.
- Feldman, D., et al., 2016. Developmental Dynamics of Rett Syndrome. *Neural Plast.* 2016, 6154080.
- Fortin, D. A., et al., 2010. Long-term potentiation-dependent spine enlargement requires synaptic Ca²⁺-permeable AMPA receptors recruited by CaM-kinase I. *J Neurosci.* 30, 11565-75.
- Glass, H. C., Ferriero, D. M., 2007. Treatment of hypoxic-ischemic encephalopathy in newborns. *Curr Treat Options Neurol.* 9, 414-23.
- Grover, L. M., Teyler, T. J., 1990. Two components of long-term potentiation induced by different patterns of afferent activation. *Nature.* 347, 477-9.
- He, L. J., et al., 2014. Conditional deletion of *Mecp2* in parvalbumin-expressing GABAergic cells results in the absence of critical period plasticity. *Nat Commun.* 5, 5036.
- Henley, J. M., Wilkinson, K. A., 2016. Synaptic AMPA receptor composition in development, plasticity and disease. *Nat Rev Neurosci.* 17, 337-50.
- Hernan, A. E., et al., 2013. Altered short-term plasticity in the prefrontal cortex after early life seizures. *Neurobiol Dis.* 50, 120-6.
- Holmes, G. L., et al., 1998. Consequences of neonatal seizures in the rat: morphological and behavioral effects. *Ann.Neurol.* 44, 845-857.
- Huang, L. T., et al., 2002. Pentylentetrazol-induced recurrent seizures in rat pups: time course on spatial learning and long-term effects. *Epilepsia.* 43, 567-73.
- Hughes, E. G., et al., 2010. Cellular and synaptic mechanisms of anti-NMDA receptor encephalitis. *J Neurosci.* 30, 5866-75.
- Isaeva, E., et al., 2013. Alteration of synaptic plasticity by neonatal seizures in rat somatosensory cortex. *Epilepsy Res.* 106, 280-3.
- Jensen, F. E., 2009. Neonatal seizures: an update on mechanisms and management. *Clin Perinatol.* 36, 881-900, vii.
- Jensen, F. E., et al., 1995. NBQX blocks acute and late epileptogenic effects of perinatal hypoxia. *Epilepsia.* 36, 966-72.
- Jensen, F. E., et al., 1992. Age dependent changes in long term seizure susceptibility and behavior after hypoxia in rats. *Epilepsia.* 33, 971-980.
- Jensen, F. E., Wang, C., 1996. Hypoxia-induced hyperexcitability in vivo and in vitro in the immature hippocampus. *Epilepsy Research.* 26(1), 131-140.
- Jiang, M., et al., 2013. Dendritic arborization and spine dynamics are abnormal in the mouse model of MECP2 duplication syndrome. *J Neurosci.* 33, 19518-33.
- Jinnah, H. A., et al., 1999. Calcium channel activation and self-biting in mice. *Proc Natl Acad Sci U S A.* 96, 15228-32.
- Kishi, N., Macklis, J. D., 2010. MeCP2 functions largely cell-autonomously, but also non-cell-autonomously, in neuronal maturation and dendritic arborization of cortical pyramidal neurons. *Exp Neurol.* 222, 51-8.
- Koh, S., et al., 2004. NBQX or topiramate treatment after perinatal hypoxia-induced seizures prevents later increases in seizure-induced neuronal injury. *Epilepsia.* 45, 569-575.
- Kramer, A. A., et al., 2012. Levels of Ca(V)1.2 L-Type Ca(2+) Channels Peak in the First Two Weeks in Rat Hippocampus Whereas Ca(V)1.3 Channels Steadily Increase through Development. *J Signal Transduct.* 2012, 597214.
- Krishnan, K., et al., 2015. MeCP2 regulates the timing of critical period plasticity that shapes functional connectivity in primary visual cortex. *Proc Natl Acad Sci U S A.* 112, E4782-91.

- Kumar, S. S., et al., 2002. A developmental switch of AMPA receptor subunits in neocortical pyramidal neurons. *J Neurosci.* 22, 3005-15.
- Li, H., et al., 2011. Loss of activity-induced phosphorylation of MeCP2 enhances synaptogenesis, LTP and spatial memory. *Nat Neurosci.* 14, 1001-8.
- Li, W., et al., 2016. Excitatory synapses are stronger in the hippocampus of Rett syndrome mice due to altered synaptic trafficking of AMPA-type glutamate receptors. *Proc Natl Acad Sci U S A.* 113, E1575-84.
- Lippman-Bell, J. J., et al., 2013. AMPA Receptor antagonist NBQX attenuates later-life epileptic seizures and autistic-like social deficits following neonatal seizures. *Epilepsia.* 54, 1922-32.
- Lippman-Bell, J. J., et al., 2016. Early-life seizures alter synaptic calcium-permeable AMPA receptor function and plasticity. *Mol Cell Neurosci.* 76, 11-20.
- Lucas, M. M., et al., 2011. Impaired cognition in rats with cortical dysplasia: additional impact of early-life seizures. *Brain.* 134, 1684-93.
- Lugo, J. N., et al., 2014. Early-life seizures result in deficits in social behavior and learning. *Exp Neurol.* 256, 74-80.
- Luikenhuis, S., et al., 2004. Expression of MeCP2 in postmitotic neurons rescues Rett syndrome in mice. *Proc Natl Acad Sci U S A.* 101, 6033-8.
- Magazanik, L. G., et al., 1997. Block of open channels of recombinant AMPA receptors and native AMPA/kainate receptors by adamantane derivatives. *J Physiol.* 505 (Pt 3), 655-63.
- Malkin, S. L., et al., 2016. Changes of AMPA receptor properties in the neocortex and hippocampus following pilocarpine-induced status epilepticus in rats. *Neuroscience.* 327, 146-55.
- Mari, F., et al., 2005. CDKL5 belongs to the same molecular pathway of MeCP2 and it is responsible for the early-onset seizure variant of Rett syndrome. *Hum Mol Genet.* 14, 1935-46.
- Martinowich, K., et al., 2003. DNA methylation-related chromatin remodeling in activity-dependent BDNF gene regulation. *Science.* 302, 890-3.
- Minchom, P., et al., 1987. Antecedents and outcome of very early neonatal seizures in infants born at or after term. *Br J Obstet Gynaecol.* 94, 431-9.
- Monyer, H., et al., 1994. Developmental and regional expression in the rat brain and functional properties of four NMDA receptors. *Neuron.* 12, 529-40.
- Moretti, P., et al., 2005. Abnormalities of social interactions and home-cage behavior in a mouse model of Rett syndrome. *Hum Mol Genet.* 14, 205-20.
- Moretti, P., et al., 2006. Learning and memory and synaptic plasticity are impaired in a mouse model of Rett syndrome. *J. Neurosci.* 26, 319-327.
- Morton, R. A., et al., 2013. Characterization of L-type voltage-gated Ca(2+) channel expression and function in developing CA3 pyramidal neurons. *Neuroscience.* 238, 59-70.
- Mukandala, G., et al., 2016. The Effects of Hypoxia and Inflammation on Synaptic Signaling in the CNS. *Brain Sci.* 6.
- Mullaney, B. C., et al., 2004. Developmental expression of methyl-CpG binding protein 2 is dynamically regulated in the rodent brain. *Neuroscience.* 123, 939-49.
- Munoz, P., et al., 2016. Inhibition of DNA Methylation Impairs Synaptic Plasticity during an Early Time Window in Rats. *Neural Plast.* 2016, 4783836.
- Neul, J. L., et al., 2010. Rett syndrome: revised diagnostic criteria and nomenclature. *Ann Neurol.* 68, 944-50.
- Park, P., et al., 2016. Calcium-Permeable AMPA Receptors Mediate the Induction of the Protein Kinase A-Dependent Component of Long-Term Potentiation in the Hippocampus. *J Neurosci.* 36, 622-31.
- Pickard, L., et al., 2000. Developmental changes in synaptic AMPA and NMDA receptor distribution and AMPA receptor subunit composition in living hippocampal neurons. *J Neurosci.* 20, 7922-31.
- Pobbe, R. L., et al., 2012. Oxytocin receptor and Mecp2 308/Y knockout mice exhibit altered expression of autism-related social behaviors. *Physiol Behav.* 107, 641-8.
- Qiu, Z., et al., 2012. The Rett syndrome protein MeCP2 regulates synaptic scaling. *J Neurosci.* 32, 989-94.
- Radzicki, D., et al., 2013. Temperature-sensitive Cav1.2 calcium channels support intrinsic firing of pyramidal neurons and provide a target for the treatment of febrile seizures. *J Neurosci.* 33, 9920-31.

- Rakhade, S. N., et al., 2012. Glutamate receptor 1 phosphorylation at serine 831 and 845 modulates seizure susceptibility and hippocampal hyperexcitability after early life seizures. *J Neurosci.* 32, 17800-12.
- Rakhade, S. N., Jensen, F. E., 2009. Epileptogenesis in the immature brain: emerging mechanisms. *Nat Rev Neurol.* 5, 380-91.
- Rakhade, S. N., et al., 2011. Development of later life spontaneous seizures in a rodent model of hypoxia-induced neonatal seizures. *Epilepsia.* 52, 753-65.
- Rakhade, S. N., et al., 2008. Early alterations of AMPA receptors mediate synaptic potentiation induced by neonatal seizures. *J Neurosci.* 28, 7979-90.
- Rusconi, L., et al., 2011. Extrasynaptic N-methyl-D-aspartate (NMDA) receptor stimulation induces cytoplasmic translocation of the CDKL5 kinase and its proteasomal degradation. *J Biol Chem.* 286, 36550-8.
- Sanchez, R. M., et al., 2001. Decreased glutamate receptor 2 expression and enhanced epileptogenesis in immature rat hippocampus after perinatal hypoxia-induced seizures. *J Neurosci.* 21, 8154-8163.
- Sayin, U., et al., 2004. Seizures in the developing brain cause adverse long-term effects on spatial learning and anxiety. *Epilepsia.* 45, 1539-1548.
- Schlick, B., et al., 2010. Voltage-activated calcium channel expression profiles in mouse brain and cultured hippocampal neurons. *Neuroscience.* 167, 786-98.
- Shahbazian, M., et al., 2002a. Mice with truncated MeCP2 recapitulate many Rett syndrome features and display hyperacetylation of histone H3. *Neuron.* 35, 243-54.
- Shahbazian, M. D., et al., 2002b. Insight into Rett syndrome: MeCP2 levels display tissue- and cell-specific differences and correlate with neuronal maturation. *Hum.Mol.Genet.* 11, 115-124.
- Shitak, R., et al., 2006. Anti-seizure efficacy of nimodipine in pentylenetetrazole and kainic acid combined seizure models in mice. *Indian J Physiol Pharmacol.* 50, 265-72.
- Shitak, R., et al., 2007. Evaluation of the modulatory role of nimodipine in seizures induced by kainic acid and pentylenetetrazole in mice. *Methods Find Exp Clin Pharmacol.* 29, 11-7.
- Siwek, M., et al., 2012. Voltage-gated Ca(2+) channel mediated Ca(2+) influx in epileptogenesis. *Adv Exp Med Biol.* 740, 1219-47.
- Speckmann, E. J., et al., 1993. Contribution of calcium ions to the generation of epileptic activity and antiepileptic calcium antagonism. *Neuropsychobiology.* 27, 122-6.
- Splawski, I., et al., 2004. Ca(V)1.2 calcium channel dysfunction causes a multisystem disorder including arrhythmia and autism. *Cell.* 119, 19-31.
- Stiglbauer, V., et al., 2017. Cav 1.3 channels play a crucial role in the formation of paroxysmal depolarization shifts in cultured hippocampal neurons. *Epilepsia.*
- Swann, J. W., 2004. The effects of seizures on the connectivity and circuitry of the developing brain. *Ment.Retard.Dev.Disabil.Res.Rev.* 10, 96-100.
- Szczurowska, E., Mares, P., 2015. An antagonist of calcium permeable AMPA receptors, IEM1460: Anticonvulsant action in immature rats? *Epilepsy Res.* 109, 106-13.
- Talos, D., et al., 2006a. Developmental regulation of alpha-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid receptor subunit expression in forebrain and relationship to regional susceptibility to hypoxic/ischemic injury. I. Rodent cerebral white matter and cortex. *Journal of Comparative Neurology.* 497, 42-61.
- Talos, D., et al., 2006b. Developmental regulation of alpha-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid receptor subunit expression in forebrain and relationship to regional susceptibility to hypoxic/ischemic injury. II. Human cerebral white matter and cortex. *Journal of Comparative Neurology.* 497, 61-77.
- Talos, D. M., et al., 2012. The Interaction Between Early Life Epilepsy and Autistic-Like Behavioral Consequences: A Role for the Mammalian Target of Rapamycin (mTOR) Pathway. *PLoS One.* 7, e35885.
- Tao, J., et al., 2009. Phosphorylation of MeCP2 at Serine 80 regulates its chromatin association and neurological function. *Proc Natl Acad Sci U S A.* 106, 4882-7.
- Tao, J., et al., 2004. Mutations in the X-linked cyclin-dependent kinase-like 5 (CDKL5/STK9) gene are associated with severe neurodevelopmental retardation. *Am J Hum Genet.* 75, 1149-54.
- Tekgul, H., et al., 2006. The current etiologic profile and neurodevelopmental outcome of seizures in term newborn infants. *Pediatrics.* 117, 1270-1280.

- Tuchman, R., 2013. Autism and social cognition in epilepsy: implications for comprehensive epilepsy care. *Curr Opin Neurol.* 26, 214-8.
- Wang, I. T., et al., 2012. Loss of CDKL5 disrupts kinome profile and event-related potentials leading to autistic-like phenotypes in mice. *Proc Natl Acad Sci U S A.* 109, 21516-21.
- Wang, P., et al., 2008. Impaired spatial learning related with decreased expression of calcium/calmodulin-dependent protein kinase IIalpha and cAMP-response element binding protein in the pentylenetetrazol-kindled rats. *Brain Res.* 1238, 108-17.
- Weaving, L. S., et al., 2004. Mutations of CDKL5 cause a severe neurodevelopmental disorder with infantile spasms and mental retardation. *Am J Hum Genet.* 75, 1079-93.
- Weng, S. M., et al., 2011. Synaptic plasticity deficits in an experimental model of rett syndrome: long-term potentiation saturation and its pharmacological reversal. *Neuroscience.* 180, 314-21.
- Wirrell, E. C., et al., 2011. Incidence and classification of new-onset epilepsy and epilepsy syndromes in children in Olmsted County, Minnesota from 1980 to 2004: A population-based study. *Epilepsy Research.* 95, 110-118.
- Xia, Y., et al., 1996. Nitric oxide synthase generates superoxide and nitric oxide in arginine-depleted cells leading to peroxynitrite-mediated cellular injury. *Proc Natl Acad Sci U S A.* 93, 6770-4.
- Yashiro, K., Philpot, B. D., 2008. Regulation of NMDA receptor subunit expression and its implications for LTD, LTP, and metaplasticity. *Neuropharmacology.* 55, 1081-94.
- Yin, H. Z., et al., 1999. Dendritic localization of Ca(2+)-permeable AMPA/kainate channels in hippocampal pyramidal neurons. *J Comp Neurol.* 409, 250-260.
- Zhang, W., et al., 2014. Loss of MeCP2 from forebrain excitatory neurons leads to cortical hyperexcitation and seizures. *J Neurosci.* 34, 2754-63.
- Zhong, X., et al., 2012. MeCP2 phosphorylation is required for modulating synaptic scaling through mGluR5. *J Neurosci.* 32, 12841-7.
- Zhou, C., et al., 2011. Hypoxia-induced neonatal seizures diminish silent synapses and long-term potentiation in hippocampal CA1 neurons. *J Neurosci.* 31, 18211-22.
- Zhou, Z., et al., 2006. Brain-specific phosphorylation of MeCP2 regulates activity-dependent Bdnf transcription, dendritic growth, and spine maturation. *Neuron.* 52, 255-69.
- Zhu, Y. C., et al., 2013. Palmitoylation-dependent CDKL5-PSD-95 interaction regulates synaptic targeting of CDKL5 and dendritic spine development. *Proc Natl Acad Sci U S A.* 110, 9118-23.

Figure Legends

Figure 1: Hypoxic Seizures (HS) in P10 rats induce phosphorylation of MeCP2 S421 and CaMKII T286 in cortex. (A) Increased MeCP2 S421 phosphorylation at 3 hrs. post-seizure induction (n=4 samples/group with 3 rat cortices pooled for one sample, p=0.003) and **(B)** increased CaMKII T286 phosphorylation at 1 hr post-seizure (n=4, p=0.009). C=normoxic controls, HS=post-seizure rats. For all figures, error bars represent standard error of mean. *p<0.05, **p<0.1, ***p<0.001, ****p<0.0001. See Suppl. Methods for HS procedure and Suppl. Fig. 1 for time course of phosphorylation relative to loading controls.

Figure 2: AMPARs mediate kainic acid (KA)-induced Ca^{2+} influx in E18+10DIV cortical and hippocampal neuronal cultures. Kainic acid (KA)-induced Ca^{2+} influx in Fura-2 loaded neurons decreased following incubation with the NMDAR antagonist D-APV in C=cortical **(A)**, KA+APV vs. KA, n=104 cells from 2 coverslips, p<0.0001) and **(B)** H=hippocampal neuronal cultures (KA+APV vs. KA, n=68 cells from 3 coverslips, p<0.0001). Bar graphs represent mean peak 340/380 excitation ratio, normalized to average of KA condition. NMDAR-sensitive Ca^{2+} influx was *further* decreased by both the AMPAR antagonist NBQX (KA+APV+NBQX, C: n=102 cells from 3 coverslips; H: n=133 cells from 5 coverslips; p<0.0001 for both) and NASPM, a blocker of Ca^{2+} permeable AMPARs (KA+APV+NASPM, C: n= 133 cells from 3 coverslips; H: n=176 cells from 6 coverslips, p<0.0001 for both), normalized to average of KA+APV condition. Ratiometric scales are left of each set, scale bar=20 μm .

Figure 3: Kainic Acid (KA)- and KCl-induced MeCP2 S421 phosphorylation is mediated by CP-AMPA and LT-VGCCs in E18+10DIV cortical and hippocampal neuronal cultures. Immunoblots demonstrating that KA still induced MeCP2 phosphorylation in the presence of D-APV in **(A)** C=cortical (n=4, p=0.0722) and **(B)** H=hippocampal (n=8, p=0.8881) cell cultures. However, MeCP2 phosphorylation was reduced from D-APV condition by adding NBQX (C: n=

4, $p < 0.0001$; H: $n = 8$, $p < 0.0001$), nimodipine (C: $n = 4$, $p < 0.0001$, H: $n = 7$, $p < 0.0001$), and/or NASPM (C: $n = 4$, $p < 0.0001$; H: $n = 6$, $p < 0.0001$). Addition of nimodipine to D-APV and NASPM did not further reduce MeCP2 S421 phosphorylation in cortical ($p = 0.973$) and hippocampal ($p = 0.790$) cultures. **(C-D)** Immunoblots demonstrating that KCl-induced phosphorylation of MeCP2 S421 cannot be reversed by treatment with D-APV alone in cortical (**C**: $n = 4$, $p = 0.9637$) and hippocampal (**D**: $n = 4$, $p = 0.373$) cultures. However, KCl-induced phosphorylation of MeCP2 S421 was reversed by NBQX alone in (C: $n = 4$, $p = 0.0069$, H: $n = 4$, $p = 0.0003$). MeCP2 phosphorylation was reduced from the D-APV treated condition with the addition NBQX (C: $n = 4$, $p = 0.0215$; H: $n = 4$, $p = 0.0082$), Nimodipine (C: $n = 4$, $p = 0.0005$; H: $n = 4$, $p = 0.0002$), and NASPM (C: $n = 4$, $p = 0.0241$; H: $n = 4$, $p = 0.0015$). Addition of nimodipine to D-APV and NASPM did not significantly further reduce p-MeCP2 S421 (C: $p = 0.4352$; H: $p = 0.8012$).

Figure 4: CaMKII T286 phosphorylation is upstream of MeCP2 S421 phosphorylation and mediated by intracellular Ca^{2+} in E18+10DIV neuronal cultures. (A-B) Representative immunoblots from cortical (**A**) and hippocampal cultures (**B**) demonstrating that KA-induced phosphorylation of MeCP2 S421 is reduced by treatment with the CaMKII inhibitor KN-93 (C: $n = 5$, $p < 0.0001$; H: $n = 5$, $p < 0.0001$), but not its inactive analog KN-92 (C: $n = 5$, $p > 0.9999$; H: $n = 5$, $p > 0.9999$). MeCP2 phosphorylation is reduced by the Ca^{2+} chelator EGTA (C: $n = 5$, $p = 0.0005$; H: $n = 5$, $p < 0.0001$). **(C-D)** MeCP2 Ser421 phosphorylation is reduced by the membrane-permeable Ca^{2+} chelator EGTA-AM (100 μM) in cortical (**C**, $64 \pm 6\%$ vs. KA+Veh 100% condition, $p = 0.0001$) and hippocampal (**D**, $53 \pm 13\%$, $p = 0.0057$) neuronal cultures. IEM-1460 (30 μM) reduces KA-induced MeCP2 phosphorylation in cortical (**C**, $76 \pm 5\%$, $p = 0.0039$) and hippocampal (**D**, $70 \pm 8\%$, $p = 0.0361$) cell cultures. $n = 6$ coverslips for cortical neurons and $n = 4$ for hippocampal neurons.

Figure 5: CaMKII T286 phosphorylation is partially mediated by CP-AMPA receptors and LT-

VGCCs in E18+10DIV cell cultures. A-B, KA-induced phosphorylation of CaMKII T286 cannot be reversed by treatment with D-APV alone in cortical (**A**) (n=4, p=0.2921) and hippocampal neuronal cultures (**B**) (n=7, p=0.5213). However, CaMKII phosphorylation was reduced from the D-APV treated condition with the addition of NBQX (C: n=4, p<0.0001; H: n=7, p<0.0001), nimodipine (C: n=4 p=0.0002; H: n=6, p<0.0001), and NASPM (C: n=4, p=0.0001; H: n=6, p<0.0001). Addition of nimodipine to D-APV and NASPM did not further reduce CaMKII T286A phosphorylation in cortex (p=0.7365) or hippocampus (p=0.9290).

Figure 6: AMPARs and LT-VGCCs mediate Hypoxic Seizure (HS)-induced MeCP2 S421

phosphorylation *in vivo* in P10 rats. Increased MeCP2 S421 phosphorylation 3 hrs. post-HS (HS+V: n=17 vs. C+V n=14, p=0.0003) can be attenuated by *in vivo* pre-treatment with the AMPAR antagonist NBQX (20 mg/kg, i.p.) (HS+NBQX: n=9, vs. HS+V, p<0.0001), the CP-AMPA blocker IEM-1460 (20 mg/kg, i.p.) (HS+IEM-1460: n=9, vs. HS+V p=0.0099), or the LT-VGCC antagonist nimodipine (10 mg/kg, i.p.) (HS+NIMO: n=9, vs. HS+V p=0.0051).